top of page
iStock-1324402385.jpg

RESURGE THERAPEUTICS

Pioneering Transformative Drug Delivery Therapies for Urology

We are a team of experts in drug delivery, engineering, clinical and business leadership.  Through collaboration with leading urologists and clinicians we are rethinking what is possible in treating large unmet urological conditions with localized drug delivery.  Our lead product is a local drug delivery therapy for treatment of lower urinary tract symptoms caused by an enlarged prostate, a condition known as benign prostatic hyperplasia.  

enlarged prostate recolored.jpg

BPH

Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia, BPH, is a common condition that affects aging men.  The prostate enlarges with age and compresses the urethra which results in urination challenges.  Left untreated it may lead to bladder or kidney problems. Approximately 40 million men in the US have BPH.  Current treatments include includes oral medications with limited efficacy and side effects or invasive and painful surgical procedures.

iStock-1022148436.jpg

OUR TECHNOLOGY

Advanced Drug Delivery Solutions

Innovation in local drug delivery therapies is at the core of what we do at Resurge Therapeutics.  Our main goal is finding ways of delivering drugs to more efficiently treat local diseases without the side effects and adherence challenges of oral medications.  Locally administered drugs also serve as an alternative to more invasive surgical interventions.

ABOUT US

Resurge Therapeutics is founded and led by an experienced 

drug delivery and urology expert team.

NEWS
 

Resurge Therapeutics Announces Compelling Six-Month Clinical Results from Novel Prostate Drug Delivery Therapy

San Jose, CA, May 2025 – Resurge Therapeutics, a privately-held life sciences company, announced promising six-month results from the initial dose cohort of the ongoing first-in-human study evaluating its novel IntraProstatic Drug Elution (IPDE) therapy. The novel therapy demonstrated meaningful improvements in both symptom severity and urinary flow rates in men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).  

​​

The results were presented by Flavio Ordones, M.D., of Tauranga, New Zealand, at the American Urology Association Annual Meeting held April 26–29, 2025, in Las Vegas. Ordones’ presentation received the “Best in Session” award in the BPH New Technology track. 

 

(View full press release)

iStock-501948853.jpg

Resurge Therapeutics mission is to pioneer transformative drug delivery therapies for urology.

2355 Paragon Drive Suite F

San Jose, CA 95131

contact@resurgetherapeutics.com

©2025 by Resurge Therapeutics.

bottom of page